Surrogate markers, atherosclerosis and cardiovascular disease prevention

International Journal of Clinical Practice

Volumn 62, Issue 7, 2008, Pages 981-987

  Wierzbicki, A S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESTYRAMINE; ESTROGEN; EZETIMIBE; FENOFIBRATE; GLIMEPIRIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; PACTIMIBE; PIOGLITAZONE; PLACEBO; PRAVASTATIN; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; ROSUVASTATIN; SIMVASTATIN; THYROXINE;

ANGIOCARDIOGRAPHY; ARTERIAL WALL THICKNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE MARKER; DRUG DOSE COMPARISON; DRUG SCREENING; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; INTIMA; LICENSING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTION; PRIORITY JOURNAL; REVIEW;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; RISK FACTORS; TREATMENT OUTCOME;

EID: 44849117820     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01794.x     Document Type: Review

References (57)

1. Pathological Determinants of Atherosclerosis (PDAY) Research Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA 1990 264 : 3018 24.
2. Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008 358 : 1431 43.
3. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986 8 : 1245 55.
4. Berkenstam A, Kristensen J, Mellstrom K et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 2008 105 : 663 7.
5. Herrington DM, Reboussin DM, Brosnihan KB et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000 343 : 522 9.
6. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998 280 : 605 13.
7. Wierzbicki AS, Chowienczyk PJ, Cockcroft JR et al. Cardiovascular risk factors and endothelial dysfunction. Clin Sci (Lond) 2004 107 : 609 15.
8. Anderson TJ, Roberts AC, Hildebrand K et al. The fate of endothelial function testing: rationale and design of the Firefighters And Their Endothelium (FATE) study. Can J Cardiol 2003 19 : 61 6.
9. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004 350 : 1387 97.
10. Meinitzer A, Seelhorst U, Wellnitz B et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 2007 53 : 273 83.
11. Lorenz MW, Markus HS, Bots ML et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007 115 : 459 67.
12. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993 87 : 1067 75.
13. Bots ML. Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies. Curr Med Res Opin 2006 22 : 2181 90.
14. Dijk JM, van der GY, Bots ML et al. Carotid intima-media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the SMART study. Eur Heart J 2006 27 : 1971 8.
15. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications.Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Diabetes 1999 48 : 383 90.
16. Bots ML, Hofman A, Grobbee DE. Increased common carotid intima-media thickness. Adaptive response or a reflection of atherosclerosis? Findings from the Rotterdam Study. Stroke 1997 28 : 2442 7.
17. Wierzbicki AS. Intervening on HDL-C: is it possible? Does it work? Int J Clin Pract 2007 61 : 1782 6.
18. Byington RP, Jukema JW, Salonen JT et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995 92 : 2419 25.
19. Sacks FM, Tonkin AM, Shepherd J et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000 102 : 1893 900.
20. Glagov S, Weisenberg E, Zarins CK et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987 316 : 1371 5.
21. Amato M, Montorsi P, Ravani A et al. Carotid intima-media thickness by B-mode ultrasound as surrogate of coronary atherosclerosis: correlation with quantitative coronary angiography and coronary intravascular ultrasound findings. Eur Heart J 2007 28 : 2094 101.
22. Berry C, L'Allier PL, Gregoire J et al. Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation 2007 115 : 1851 7.
23. Ballantyne CM, Raichlen JS, Nicholls SJ et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography. A study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation 2008 Epub ahead of print PM, Fonseca FA, Genest J et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007 100 : 1659 64.
24. TheHEART org. JUPITER Halted: Rosuvastatin Significantly Reduces Cardiovascular Morbidity and Mortality, 31 March 2008. http://www.theheart.org/ article/852735.do (accessed April 2008).
25. Kastelein JJ, van Leuven SI, Burgess L et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007 16 : 1620 30.
26. Nissen SE, Tardif JC, Nicholls SJ et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007 356 : 1304 16.
27. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357 : 2109 22.
28. Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006 296 : 2572 81.
29. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008 299 : 1561 73.
30. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 366 : 1279 89.
31. Bertrand OF, Despres JP, Poirier P. Vein-Coronary Atherosclerosis and Rosiglitazone after Bypass Surgery: the VICTORY Trial. ClinicalTrials gov, 17 July 2006. http://clinicaltrials.gov/ct2/show/NCT00169832?intr= %22Rosiglitazone%22&rank=32 (accessed April 2008).
32. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007 298 : 1189 95.
33. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007 357 : 28 38.
34. Nissen SE, Nicholls SJ, Wolski K et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008 299 : 1547 60.
35. Sanofi-Aventis. Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes (CRESCENDO). ClinicalTrials gov. http://www.clinicaltrials.gov/ct/show/NCT00263042 (accessed July 2006).
36. Arad Y, Goodman KJ, Roth M et al. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol 2005 46 : 158 65.
37. Elkeles RS, Godsland IF, Rubens MB et al. The progress of coronary heart disease in type 2 diabetes as measured by coronary calcium score from electron beam computed tomography (EBCT): the PREDICT study. Atherosclerosis 2008 197 : 777 83.
38. Raggi P, Callister TQ, Davidson M et al. Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. Am Heart J 2001 141 : 722 6.
39. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 2008 358 : 1504 7.
40. Drazen JM, Jarcho JA, Morrissey S et al. Cholesterol lowering and ezetimibe. N Engl J Med 2008 358 : 1507 8.
41. Smilde TJ, van Wissen S, Wollersheim H et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001 357 : 577 81.
42. Crouse JR III., Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007 297 : 1344 53.
43. Jackevicius CA, Tu JV, Ross JS et al. Use of ezetimibe in the United States and Canada. N Engl J Med 2008 358 : 1819 28.
44. Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005 294 : 2437 45.
45. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001 345 : 1583 92.
46. Brown BG, Zambon A, Poulin D et al. Use of niacin, statins, and resins in patients with combined hyperlipidemia. Am J Cardiol 1998 81 : 52B 9B.
47. Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004 110 : 3512 7.
48. National Heart LaBIN. Niacin plus statin to prevent vascular events: AIM-HIGH. ClinicalTrials gov. http://www.clinicaltrials.gov/ct/show/NCT00120289 (accessed July 2006).
49. Pfeffer MA, Sacks FM, Moye LA et al. Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol 1995 76 : 98C 106C.
50. Long-term Intervention with Pravastatin in Ishemic Disease (LIPID) Investigators. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002 359 : 1379 87.
51. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 279 : 1615 22.
52. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005 366 : 1849 61.
53. Wierzbicki AS. FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 2006 60 : 442 9.
54. Viljoen A, Wierzbicki AS. Enhanced LDL-C reduction: lower is better. Does it matter how? Int J Clin Pract 2008 62 : 518 20.
55. MacMahon M, Kirkpatrick C, Cummings CE et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis 2000 10 : 195 203.
56. National Institute for Health and Clinical Excellence. Ezetimibe for the Treatment of Primary (Heterozygous-Familial and Non-familial) Hypercholesterolaemia: Technology Appraisal 132. London : Her Majesty's Stationery Office, 2007.
57. American College of Cardiology. ENHANCE Trial Results: Statins Remain First Line, 30 March 2008. http://www.acc.org/enhance_statement.htm (accessed April 2008).